Neovacs SA (FR:ALNEV) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neovacs SA, a French biotech firm focused on inflammatory and autoimmune diseases, has announced a capital reduction to offset losses by decreasing the nominal share value from 0.005 euro to 0.0005 euro. The company’s share capital now stands at 125,968.0985 euros, divided into 251,936,197 shares. Investors are cautioned about potential share dilution and capital loss due to the company’s dilutive financing operations.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.